The Evolving Needs of Therapeutic mRNA Developers
Insights on the next wave of challenges mRNA innovators face as an increasing number of therapeutics move through the pipeline.
Behind the Headlines Panel Discussion
Christian Cobaugh, Ph.D., Vernal Biosciences founder and chief scientific officer, participated in a dynamic panel moderated by Chris Spivey, director of Industry Relations and Strategic Partnerships at MJH Life Sciences. The discussion considered news impacting the industry, such as investment trends, policy realignments, and vaccine funding.
Lipid Nanoparticle Platform Delivers mRNA to the Brain Through the Blood-Brain Barrier
Researchers at the Icahn School of Medicine at Mount Sinai say they have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a challenge that the protective nature of the blood-brain barrier has long limited.
Monitoring mRNA Vaccine Antigen Expression in vivo Using PET/CT
Noninvasive visualization of the distribution and persistence of mRNA vaccine antigen expression in mammalian systems has implications for developing and evaluating future mRNA vaccines.
New mRNA Vaccines Target a Host of Viral and Bacterial Pathogens
Numerous innovators worldwide are leveraging state-of-the-art mRNA platforms to address an increasingly diverse range of conditions, from urinary tract infections and gonorrhea to norovirus.
Programmable mRNA Therapeutics for Controlled Epigenomic Modulation of Single and Multiplexed Gene Expression in Diverse Diseases
Progress is being made in creating a modular platform to design programmable mRNA therapeutics, Epigenomic Controllers (EC), that control gene expression through directed epigenetic change.